{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T21:37:09Z","timestamp":1781041029085,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sub-retinal fluid (SRF) has been discussed as a protective factor against macular atrophy in eyes with neovascular age-related macular degeneration (nAMD).To gauge the impact of SRF on macular atrophy, a database of 310 nAMD eyes was screened for eyes manifesting an SRF-only phenotype under treat &amp; extend anti-VEGF treatment, defined as nAMD expressing CNV exudation beyond the three monthly anti-VEGF loading doses by SRF only without any signs of exudative intra-retinal fluid (IRF) for \u22653 years. Incidence of macular atrophy and treatment responses were evaluated on multimodal imaging, including optical coherence tomography (OCT), blue autofluorescence (BAF) and near-infrared (NIR) confocal scanning laser ophthalmoscopy and fluorescence and indocyanine green angiography (FAG\/ICGA). In total, 27\u00a0eyes (8.7%) of 26 patients with a mean follow-up of 4.2\u2009\u00b1\u20090.9 (3\u20135) years met the inclusion criteria. Mean age was 72\u2009\u00b1\u20096 (range: 61\u201386) years. The SRF only phenotype was seen from baseline in 14 eyes (52%), and in 13 eyes (48%) after a mean 1.0\u2009\u00b1\u20091.3 (1\u20133) injections. In years 1 to 5, mean 7.5, 5.9, 6.1, 6.1 and 7.0 anti-VEGF injections were given (p\u2009=\u20090.33). Cumulative macular atrophy incidence was 11.5% at year 1, 15.4% throughout years 2 to 4, and 22.4% at year 5. In conclusion, eyes manifesting activity by SRF only in treat &amp; extend anti-VEGF regimen for nAMD seem to exhibit rather low rates of macular atrophy during long-term follow-up. SRF might be an indicator of a more benign form of nAMD.<\/jats:p>","DOI":"10.1038\/s41598-020-64901-9","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T10:21:14Z","timestamp":1589538074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat &amp; Extend Anti-Vascular Endothelial Growth Factor Inhibitors"],"prefix":"10.1038","volume":"10","author":[{"given":"Jakob","family":"Siedlecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schworm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Kreutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Luft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten U.","family":"Kortuem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda G.","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"64901_CR1","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1021\/acs.molpharmaceut.5b00775","volume":"13","author":"N Hodgson","year":"2016","unstructured":"Hodgson, N. et al. Economic and Quality of Life Benefits of Anti-VEGF Therapy. Mol. Pharm. 13, 2877\u20132880, https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00775 (2016).","journal-title":"Mol. Pharm."},{"key":"64901_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","volume":"121","author":"JE Grunwald","year":"2014","unstructured":"Grunwald, J. E. et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121, 150\u2013161, https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.015 (2014).","journal-title":"Ophthalmology"},{"key":"64901_CR3","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/iae.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund, K. B. et al. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina (Philadelphia, Pa.) 35, 1489\u20131506, https:\/\/doi.org\/10.1097\/iae.0000000000000627 (2015).","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"64901_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth, U., Waldstein, S. M., Deak, G. G., Kundi, M. & Simader, C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology 122, 822\u2013832, https:\/\/doi.org\/10.1016\/j.ophtha.2014.11.017 (2015).","journal-title":"Ophthalmology"},{"key":"64901_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma, S. et al. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123, 865\u2013875, https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.002 (2016).","journal-title":"Ophthalmology"},{"key":"64901_CR6","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe, G. J. et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120, 1860\u20131870, https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.073 (2013).","journal-title":"Ophthalmology"},{"key":"64901_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.sjopt.2014.03.001","volume":"28","author":"KV Bhavsar","year":"2014","unstructured":"Bhavsar, K. V. & Freund, K. B. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi journal of ophthalmology: official journal of the Saudi Ophthalmological Society 28, 129\u2013133, https:\/\/doi.org\/10.1016\/j.sjopt.2014.03.001 (2014).","journal-title":"Saudi journal of ophthalmology: official journal of the Saudi Ophthalmological Society"},{"key":"64901_CR8","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/iae.0000000000000465","volume":"35","author":"C Gianniou","year":"2015","unstructured":"Gianniou, C., Dirani, A., Jang, L. & Mantel, I. REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome. Retina (Philadelphia, Pa.) 35, 1195\u20131201, https:\/\/doi.org\/10.1097\/iae.0000000000000465 (2015).","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"64901_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe, G. J. et al. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 126, 252\u2013260, https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.035 (2019).","journal-title":"Ophthalmology"},{"key":"64901_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.11.025","author":"RH Guymer","year":"2018","unstructured":"Guymer, R. H. et al. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025 (2018).","journal-title":"Ophthalmology"},{"key":"64901_CR11","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.ophtha.2012.06.056","volume":"119","author":"SS Wickremasinghe","year":"2012","unstructured":"Wickremasinghe, S. S. et al. Predictors of AMD treatment response. Ophthalmology 119, 2413\u20132414.e2415, https:\/\/doi.org\/10.1016\/j.ophtha.2012.06.056 (2012).","journal-title":"Ophthalmology"},{"key":"64901_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IAE.0b013e3182657fff","volume":"33","author":"N Lois","year":"2013","unstructured":"Lois, N., McBain, V., Abdelkader, E., Scott, N. W. & Kumari, R. Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy. Retina (Philadelphia, Pa.) 33, 13\u201322, https:\/\/doi.org\/10.1097\/IAE.0b013e3182657fff (2013).","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"64901_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ajo.2018.05.008","volume":"192","author":"NS Abdelfattah","year":"2018","unstructured":"Abdelfattah, N. S. et al. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. Am J Ophthalmol 192, 84\u201390, https:\/\/doi.org\/10.1016\/j.ajo.2018.05.008 (2018).","journal-title":"Am J Ophthalmol"},{"key":"64901_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.07.013","author":"C Bailey","year":"2018","unstructured":"Bailey, C. et al. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial. Ophthalmology https:\/\/doi.org\/10.1016\/j.ophtha.2018.07.013 (2018).","journal-title":"Ophthalmology"},{"key":"64901_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda, S. R. et al. Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology 125, 537\u2013548, https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.028 (2018).","journal-title":"Ophthalmology"},{"key":"64901_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","volume":"132","author":"GS Ying","year":"2014","unstructured":"Ying, G. S. et al. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA ophthalmology 132, 915\u2013921, https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.1019 (2014).","journal-title":"JAMA ophthalmology"},{"key":"64901_CR17","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R. & Zhang, K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120, 2292\u20132299, https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046 (2013).","journal-title":"Ophthalmology"},{"key":"64901_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ophtha.2014.07.046","volume":"122","author":"E Tanaka","year":"2015","unstructured":"Tanaka, E., Chaikitmongkol, V., Bressler, S. B. & Bressler, N. M. Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology 122, 153\u2013161, https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.046 (2015).","journal-title":"Ophthalmology"},{"key":"64901_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1097\/IAE.0b013e3181d50cbf","volume":"30","author":"M Engelbert","year":"2010","unstructured":"Engelbert, M., Zweifel, S. A. & Freund, K. B. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified \u201ctreat and extend\u201d dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina (Philadelphia, Pa.) 30, 1368\u20131375, https:\/\/doi.org\/10.1097\/IAE.0b013e3181d50cbf (2010).","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"64901_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","volume":"124","author":"NS Abdelfattah","year":"2017","unstructured":"Abdelfattah, N. S. et al. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology 124, 215\u2013223, https:\/\/doi.org\/10.1016\/j.ophtha.2016.10.002 (2017).","journal-title":"Ophthalmology"},{"key":"64901_CR21","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research, G. et al.","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research, G. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119, 1388\u20131398, https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053 (2012).","journal-title":"Ophthalmology"},{"key":"64901_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","volume":"124","author":"JE Grunwald","year":"2017","unstructured":"Grunwald, J. E. et al. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 124, 97\u2013104, https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.012 (2017).","journal-title":"Ophthalmology"},{"key":"64901_CR23","doi-asserted-by":"publisher","unstructured":"Mantel, I. et al. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. Retina (Philadelphia, Pa.), https:\/\/doi.org\/10.1097\/iae.0000000000002054 (2018).","DOI":"10.1097\/iae.0000000000002054"},{"key":"64901_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","volume":"159","author":"C Schutze","year":"2015","unstructured":"Schutze, C. et al. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 159, 1100\u20131114.e1101, https:\/\/doi.org\/10.1016\/j.ajo.2015.02.020 (2015).","journal-title":"Am J Ophthalmol"},{"key":"64901_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.oret.2017.10.010","volume":"2","author":"A Li","year":"2018","unstructured":"Li, A. et al. Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti&#x2013;Vascular Endothelial Growth Factor. Ophthalmology Retina 2, 550\u2013557, https:\/\/doi.org\/10.1016\/j.oret.2017.10.010 (2018).","journal-title":"Ophthalmology Retina"},{"key":"64901_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/aos.13522","volume":"95","author":"K Berg","year":"2017","unstructured":"Berg, K., Roald, A. B., Navaratnam, J. & Bragadottir, R. An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta ophthalmologica 95, 796\u2013802, https:\/\/doi.org\/10.1111\/aos.13522 (2017).","journal-title":"Acta ophthalmologica"},{"key":"64901_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0015-6","volume":"1","author":"E Dhrami-Gavazi","year":"2015","unstructured":"Dhrami-Gavazi, E., Balaratnasingam, C., Lee, W. & Freund, K. B. Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration. Int J Retina Vitreous 1, 15, https:\/\/doi.org\/10.1186\/s40942-015-0015-6 (2015).","journal-title":"Int J Retina Vitreous"},{"key":"64901_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ajo.2017.07.009","volume":"182","author":"V Capuano","year":"2017","unstructured":"Capuano, V. et al. Treatment-Naive Quiescent Choroidal Neovascularization in Geographic Atrophy Secondary to Nonexudative Age-Related Macular Degeneration. Am J Ophthalmol 182, 45\u201355, https:\/\/doi.org\/10.1016\/j.ajo.2017.07.009 (2017).","journal-title":"Am J Ophthalmol"},{"key":"64901_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/iae.0000000000000374","volume":"35","author":"L Xu","year":"2015","unstructured":"Xu, L. et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina 35, 176\u2013186, https:\/\/doi.org\/10.1097\/iae.0000000000000374 (2015).","journal-title":"Retina"},{"key":"64901_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1097\/iae.0000000000001766","volume":"38","author":"JG Christenbury","year":"2018","unstructured":"Christenbury, J. G. et al. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis. Retina (Philadelphia, Pa.) 38, 1276\u20131288, https:\/\/doi.org\/10.1097\/iae.0000000000001766 (2018).","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"64901_CR31","doi-asserted-by":"publisher","first-page":"e0216304","DOI":"10.1371\/journal.pone.0216304","volume":"14","author":"Y Nakano","year":"2019","unstructured":"Nakano, Y. et al. Vascular maturity of type 1 and type 2 choroidal neovascularization evaluated by optical coherence tomography angiography. PloS one 14, e0216304, https:\/\/doi.org\/10.1371\/journal.pone.0216304 (2019).","journal-title":"PloS one"},{"key":"64901_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00417-017-3595-z","volume":"255","author":"J Siedlecki","year":"2017","unstructured":"Siedlecki, J. et al. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology 255, 963\u2013972, https:\/\/doi.org\/10.1007\/s00417-017-3595-z (2017).","journal-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology"},{"key":"64901_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","volume":"125","author":"SD Adrean","year":"2018","unstructured":"Adrean, S. D., Chaili, S., Ramkumar, H., Pirouz, A. & Grant, S. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti&#x2013;VEGF Injections Using a Treat-Extend-Stop Protocol. Ophthalmology 125, 1047\u20131053, https:\/\/doi.org\/10.1016\/j.ophtha.2018.01.012 (2018).","journal-title":"Ophthalmology"},{"key":"64901_CR34","doi-asserted-by":"publisher","unstructured":"Roh, M. et al. Microperimetry in age-related macular degeneration: association with macular morphology assessed by optical coherence tomography. The British journal of ophthalmology, https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313316 (2019).","DOI":"10.1136\/bjophthalmol-2018-313316"},{"key":"64901_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/tvst.8.6.3","volume":"8","author":"AJ Wightman","year":"2019","unstructured":"Wightman, A. J. et al. Presymptomatic Retinal Sensitivity Changes in Intermediate Age-Related Macular Degeneration Associated With New Retinal Fluid. Transl Vis Sci Technol 8, 3, https:\/\/doi.org\/10.1167\/tvst.8.6.3 (2019).","journal-title":"Transl Vis Sci Technol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64901-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64901-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64901-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T10:25:46Z","timestamp":1670322346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64901-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64901"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64901-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"1 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No author reports any financial interest relevant to this study. Jakob Siedlecki received previous speaker fees and travel expenses from Novartis Pharma GmbH, Carl Zeiss Meditec AG, Oculentis OSD Medical GmbH and Pharm-Allergan GmbH. Jakob Siedlecki received personal consultation fees from Bayer AG. Benedikt Schworm received previous speaker fees and travel expenses from Novartis Pharma GmbH and Topcon Corporation. Thomas C Kreutzer received previous speaker fees from Alcon Pharma GmbH. Thomas C Kreutzer received personal consultation fees from Novartis Pharma GmbH and Bayer AG. Thomas C Kreutzer received travel reimbursement from D.O.R.C. (International) B.V. Nikolaus Luft received income from honoraria as a lecturer from Alcon Laboratories Inc., NIDEK Co. Ltd and CenterVue SpA. Karsten Kortuem received previous speaker fees and\/or travel expenses from Novartis Pharma GmbH, Bayer AG, and Alcon Pharma GmbH. Karsten Kort\u00fcm received personal consultation fees from Big Picture Medical. Karsten Kort\u00fcm received travel expenses from Pharm-Allergan GmbH and Heidelberg Engineering GmbH. Ricarda Schumann received previous speaker fees and travel expenses from Bayer AG, Novartis Pharma GmbH, Pharm-Allergan GmbH, Heidelberg Engineering GmbH, and Carl Zeiss Meditec AG. Armin Wolf received previous speaker fees and research funds from Novartis Pharma GmbH, Oertli AG, Bayer AG, Pharm-Allergan GmbH and Alimera Sciences Ophthalmologie GmbH. Siegfried Priglinger received previous speaker fees and\/or travel expenses from Novartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharma GmbH and Pharm-Allergan GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8036"}}